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Abstract
Detailed knowledge about differentiation
syndrome (DS) has remained limited. There
are 2 large studies conducted by the Spanish
workgroup PETHEMA (Programa Español de
Tratamientos en Hematología; Spanish
Program on Hematology Treatments) and the
European group trial (LPA 96-99 and APL 93)
in which the incidence, characteristics, prog-
nostic factors and outcome of patients develop-
ing DS are evaluated. Both have described the
median time of DS development between 10
and 12 days. The severity of the DS has been
evaluated in the study conducted by PETHEMA,
and severe DS usually occurs at the beginning
of the treatment (median of 6 days), as com-
pared with moderate DS (median of 15 days).
We report here in two cases of late severe DS,
with late diagnosis due to both time and form
of presentation. We discuss the physiopatholo-
gy, clinical presentation, prophylaxis and treat-
ment of DS.
Introduction
The differentiation syndrome (DS) is the
main life threatening complication of the
acute promyelocytic leukemia (APL) treatment
with all trans retinoic acid (ATRA).
The incidence of DS varies between 2 to
27%.1 This variation is mainly due to different
diagnostic criteria used among studies.2-5
The symptoms/signs that should lead high to
suspicion of DS include dyspnea, edema, unex-
plained fever, hypotension, pulmonary infil-
trates in chest radiography, pleuro-pericardial
effusion, weight gain higher than 5 kg and/or
vascular leak syndrome leading to acute renal
failure.1 However, the diagnosis is mostly
based on the presence of the above clinical
and/or radiological criteria and supported by
the response to early therapy to corticos-
teroids. In addition, some authors consider
that if 4 or more of the above-referred symp-
toms were present, the diagnosis would be
severe DS.3 The differential diagnosis should
always include lung infection, sepsis, throm-
boembolism and heart failure, and is more
challenging when time of presentation isn’t
the expected.
The median time to the development of
symptoms after ATRA treatment varies
between 2 to 21 days, with a median period of
10 days. The PETHEMA (Programa Español de
Tratamientos en Hematología; Spanish
Program on Hematology Treatments) trial
identified two types of DS,1 named early, when
it occurs within the first 7 days after starting
ATRA, and late DS if the syndrome is developed
after the first 7 days. In the same PETHEMA
trial, the presence of hypotension, unex-
plained fever, pericardial effusion and renal
failure were associated with late and severe
DS. Although the development of severe DS is
still associated with a considerable increase in
morbidity and mortality during induction
(nearly 1% in most studies) the suspicion and
the early treatment with corticosteroids have
significantly reduced the mortality rate of this
complication.1
In the present article we report two cases of
late severe DS, with late diagnosis due to both
time and form of presentation.
Case Report
The first patient, a 53 years old man, was
diagnosed of high risk microgranular variant
APL, presenting gingivorrhagia and fever.
Anemia (Hb: 7.8 g/dL), more than 10×109/L
leucocytes (11.8×109/L), and thrombocythope-
nia (platelets: 2.75×109/L) were present as
well as coagulopathy (prothrombine time: 54%;
fibrinogen: 114 mg/dL). The bone marrow aspi-
rate showed infiltration by 93% of promyelo-
cytes, and 80% of them were hypogranular. The
diagnosis was confirmed by conventional cyto-
genetic, FISH and molecular studies, identify-
ing the t(15,17) and PML/RAR (bcr3) isoform.
The patient was included in the LPA 2005
PETHEMA protocol and received idarrubicin,
12 mg/m2 on days 2, 4, 6 and 8 and ATRA, 45
mg/m2 since day 1. According to the protocol,
the patient received dexamethasone at dose of
5 mg/12 hours during 15 days as DS prophylax-
is because of leucocytes count at diagnosis
was >5×109/L.6
Twenty-four hours after stopping dexam-
ethasone, when he had just recovered from
neutropenia (neutrophils: 1.2×109/L), the
patient developed fever without any clinical
focus or microbiological documentation.
Although wide spectrum antibiotics (piper-
azilin-tazobactam and teicoplanin) were
administered, febrile syndrome was main-
tained. Six days later, on day 22, with neu-
trophil counts of 2.8×109/L, the patient devel-
oped hemodynamic instability with main-
tained hypotension, tachycardia, tachypnea
and oliguria with fluid retention, respiratory
insufficiency and evidence of hepatic failure.
The chest radiography showed bilateral alveo-
lar infiltrates and venocapillary hypertension
signs. The patient was admitted to the
Intensive Care Unit (ICU), requiring invasive
mechanical ventilation and vasoactive drugs.
At that moment, in absence of any microbio-
logical documentation, late DS was suspected
and ATRA was discontinued. Dexamethasone
was administered and significant clinical and
radiological improvement was observed 4 days
after initiation. After complete recovery, ATRA
was reintroduced without further complica-
tions. Eight months after achieving molecular
complete remission (CR), the patient relapsed
with central nervous system involvement, and
promyelocytic infiltration was detected in the
cerebrospinal fluid analysis. Rescue therapy,
that included arsenic trioxide (ATO) plus
intrathecal liposomal cytarabine, leaded to
achievement of molecular remission and the
patient received allogeneic stem cell trans-
plantation. At the present time, he remains
and disease free, 20 months after transplanta-
tion. The second patient was a 56 years old
lady, diagnosed of low risk APL based on labo-
ratory investigation due to hemorrhagic
diathesis and fever. At diagnosis she presented
anemia (Hb: 7.8 g/dL), leucopenia (0.4×109/L)
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and thrombocytopenia (platelets: 46×109/L).
The bone marrow aspirate showed 38% of
blasts, all of them abnormal promyelocytes,
and the diagnosis was confirmed by cytogenet-
ic and molecular analysis, detecting t(15,17)
and PML/RAR (bcr1) isoform, respectively.
She was also included in the LPA 2005
PETHEMA protocol and received idarrubicin 12
mg/m2 days 2, 4, 6 and 8 and ATRA 45 mg/m2
since day 1. Since it was classified as of low
risk, no DS prophylaxis was required.
Seventeen days after treatment initiation,
the patient developed fever with no clinical
focus and no microbiologic documentation.
Wide spectrum antibiotics (piperacilin/
tazobactam, teicoplanin and amikacin) were
administered without improvement. At day
+22, when granulocyte count started to recover
(0.350×109/L), the patient evidenced crepi-
tants on right pulmonary base, without dysp-
noea or cough. Bilateral pulmonary infiltrates
were observed in thorax X-ray and the comput-
erized tomography reported the presence of
bilateral pulmonary opacities, with areas of
unpolished glass. This was radiologically sug-
gestive of fungal infection and empiric treat-
ment with B-amphotericin, cotrimoxazol and
oseltamivir was given together with enlarged
spectrum antibiotics.
Seven days later, on day +28, the patient
developed respiratory failure with dyspnea,
requiring large debit oxigenotherapy.
Intensive care unit admission was required,
requiring non-invasive mechanical ventila-
tion. At that time, DS was suspected and ATRA
was discontinued starting treatment with dex-
amethasone at dose of 10 mg twice per day.
Forty-eight hours later, significant improve-
ment was observed, with disappearance of
fever and respiratory symptoms. ATRA was
reintroduced during the consolidation without
any further complications.
Discussion
The introduction of ATRA for the treatment
of APL has been one of the most significant
advances in the management of hematologic
neoplastic diseases. APL is, at the present
time, the most curable form of adult myeloid
leukemia, reaching a 5-years disease free sur-
vival of 70-80%.7-11 However, DS is probably the
most significant ATRA-related toxicity. 
The median time of DS presentation is 10
days. Here we report two late DS, developed on
day +22 in both cases.  Although late DS has
been reported by Montesinos et al.1 analyzing
two PETHEMA studies (LPA 96 and LPA 99) by
the PETHEMA group (0-46 days) and by the
European group (1-35 days),2 the median time
of presentation was not in any study superior
to 12 days. In the first case the patient had leu-
cocytosis at diagnosis and he received dexam-
ethasone as DS prophylaxis according to the
protocol. This fact could have contributed to
the delayed development of DS because the
febrile syndrome with respiratory compromise
and hypotension appeared four days after
steroids discontinuation, and at that time the
patient had already recovered from neutrope-
nia, which made DS less probable. In the sec-
ond-one case, the patient was not previously
treated with prophylactic dexamethasone due
to low risk classification, but the symptoms
were coincidental with recovery from aplasia,
which lead us to first suspect of a granulocyte
recovery-related symptomatology. It was due to
progressive clinic deterioration with respirato-
ry symptoms that we first suspect of DS.
Prophylactic use and duration of corticos-
teroids stills controversial, and in fact, our
first patient received prophylaxis with dexam-
ethasone but he developed later DS, leading
us to question its utility. LPA 96 PETHEMA
protocol recommended the prophylactic
administration of steroids during 7 days; the
LPA 99 protocol extended this recommenda-
tion to 15 days, and the current protocol, LPA
2005, indicates prophylaxis in all patients
with more than 5×109/L during 15 days. In our
case, though the prophylactic therapy pre-
vented the DS during the first 15 days of treat-
ment and the syndrome started just after cor-
ticosteroid discontinuation, making us to
question if in high-risk patients it would be
useful to keep corticosteroids during all
induction treatment. Corticosteroids might
prevent pulmonary infiltration of APL cells via
reduction of the alveolar chemokine secretion
and thereby might prevent the development of
DS.12 However, due to the fact that dexam-
ethasone does not reduce the chemokine pro-
duction by differentiating APL cells it may be
less effective during treatment of installed
DS,12 so its utility seems to be more evident
as prophylaxis than when DS is developed.
Although the impact of administration of
dexamethasone in mortality rate is not well
supported in different studies,1,3 our patients
developed severe DS according to the PETHE-
MA criteria,1 and it is well recognized this fact
as related with higher mortality: 27% vs 7% in
patients with severe DS vs no severe DS,
respectively.1
Concerning the question if the use of pro-
phylactic corticosteroids in all patients is
advantageous this should be settled in ran-
domized studies, also considering the use of
corticosteroids less toxic than dexametha-
sone, i.e. prednisone, taking into account its
potential efficacy in this setting and that
infectious complications did not apparently
increased with its use.13
There is no consensus about the presence of
risk factors predicting the development of DS.
Some studies found no associated risk
factors,2,13-15 while others suggest that the
white blood cells count at diagnosis and during
induction can be the only important risk
factor.1,3
Analysis of PETHEMA studies identified
other risk factors in a series with more than
700 patients with APL such as abnormal serum
creatinine,1 FLT3-ITD mutations, hypogranular
variant (M3v), short PML/RARa isoforms, and
male gender.1 CD13 expression was also corre-
lated with DS in other study.11 The first patient
here reported presented leukocytosis at diag-
nosis, and in addition, he was a male who had
also the hypogranular variant of APL. However,
the second one had no any previous risk fac-
tors predicting DS but the syndrome was evi-
dent twenty-two days after ATRA initiation,
just when she was recovering of neutropenia. 
Finally the mortality of DS is currently very
low (1%), mostly due to early corticosteroids
treatment, together with the concomitant use
of chemotherapy associated to ATRA.2,11
However the development of this complication
has been associated with other complications,
such as increase in morbidity and
extramedullary relapses.1,2,8,16,17 In our first
patient, extramedullar relapse at CNS
occurred, eight months after molecular CR
achievement. One hypothesis is that this is
related with ATRA-induced modulation of
adhesion molecules. If DS is a syndrome of tis-
sue infiltration by maturing myeloid cells it is
easy to understand how certain sanctuary sites
may be capable of withstanding the
antileukemic effect of consolidation chemo -
therapy.8
Conclusions
In conclusion, DS is a relatively frequent
and serious complication in patients with APL,
and the time of presentation can largely vary.
We should consider DS in all patients with
unexplained fever during the ATRA treatment,
regardless of the time of presentation.
Although the prophylaxis with steroids,
through the reduction of incidence of severe
DS, could have an indirect impact in the mor-
tality rate of APL patients, its use in all patients
should be settled in randomized trials. 
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